Objective: Adjuvant treatment with imatinib mesylate is an effective treatment for gastrointestinal stromal tumor. However, 50% of patients with gastrointestinal stromal tumor can be cured by surgery alone; hence, risk stratification for therapy with imatinib mesylate is the next challenge. Previously, using a proteomic approach, we discovered a potential prognostic biomarker for gastrointestinal stromal tumor, pfetin, and immunohistochemically validated its clinical utility using our original monoclonal antibody. In the present study, we examine the usefulness of a commercially available polyclonal antibody against pfetin. Methods: Western blotting and immunohistochemistry were performed using surgical specimens of primary tissues from gastrointestinal stromal tumor patients using a polyclonal antibody against pfetin and our original monoclonal antibody. Formalin-fixed and paraffin-embedded primary tissue sections from 112 gastrointestinal stromal tumor patients were subjected to immunohistochemistry. The immunohistochemistry results were integrated with the clinicopathological observations. Results: Western blotting revealed that both antibodies recognized multiple post-translationally modified pfetin isoforms. The immunohistochemical study with the commercial antibody demonstrated that the disease-free survival rate was 88 and 56% for pfetin-positive and pfetinnegative patients, respectively. Univariate and multivariate analyses showed that pfetin expression as measured by the commercial antibody was a significant and independent prognostic factor among the clinico-pathological parameters examined. Of the 112 gastrointestinal stromal tumor cases examined, 13 yielded discordant results between the commercial antibody and our original antibody, and there were no significantly different clinical or pathological factors to account for this discrepancy. Conclusions: Our observations suggest that the pfetin expression level assessed by the commercial antibody could be a prognostic biomarker in gastrointestinal stromal tumors.
INTRODUCTION
Gastrointestinal stromal tumor (GIST) is the most common primary mesenchymal malignancy of the gastrointestinal tract, with an incidence of 15 per 1 000 000 people (1) . GIST is characterized by the presence of mutations in receptor tyrosine kinases; 80% of GISTs harbor an activating mutation in proto-oncogene c-kit (C-KIT) and 10% in platelet-derived growth factor receptor alpha polypeptide (PDGFRA) (1) . The use of imatinib mesylate (Gleevec; Novartis), a receptor tyrosine kinase inhibitor, was effective in patients with recurrent and metastatic GIST (2, 3) , and adjuvant imatinib mesylate treatment prolonged the time to recurrence (4) . However, 60% of GIST patients can be cured by surgical resection alone, and treatment with imatinib mesylate may, therefore, benefit only a limited number of patients (5) . Thus, estimation of the risk of recurrence becomes more important in the management of operable GIST. Tumor size, mitosis count and tumor site are considered important factors in the estimation of recurrence risk, and the analysis of pooled population-based cohorts have proved their efficacy (5) . In contrast, no practical molecular biomarkers can be considered independent prognostic parameters.
We previously identified a novel prognostic biomarker, namely pfetin ( potassium channel tetramerization domain containing 12, KCTD12), using a proteomic approach (6) . Pfetin was originally discovered as a gene in the fetal cochlea and brain (7) . Recent reports have demonstrated that pfetin binds to the auxiliary GABA B receptor subunits in the brain (8, 9) . However, the association of pfetin with malignant disease was not established until our studies. We developed a monoclonal antibody against pfetin and immunohistochemically validated the results of our proteomics study (10 -12) . Using the monoclonal antibody in 371 GIST cases, we demonstrated that the disease-free survival rate was 94.5% for patients with pfetin-positive primary tumors and 56.5% for those whose primary tumors were pfetin-negative (11, 12) . We concluded that pfetin is a novel favorable biomarker in GIST. Further validation of this premise is the next challenge.
In this study, we immunohistochemically measured pfetin expression in the primary tumors of GIST patients using a commercial antibody. We found that the pfetin level measured by the commercial antibody significantly correlated with favorable prognosis in GIST. The use of a commercial antibody will facilitate a multi-center validation study of the role of pfetin in GIST.
PATIENTS AND METHODS

PATIENTS
This study included the primary tumor tissues of 40 GIST patients who underwent surgery at the Juntendo University Shizuoka Hospital from 1995 to 2009, and those of 72 GIST patients who underwent surgery at the Juntendo University Hospital from 2000 to 2010. All the patients underwent resection with curative intent and adjuvant treatments were not given. Diagnosis was based on the WHO classification system for soft tissue tumors: tumor size, the presence of necrosis, differentiation, mitotic rate, mindbomb E3 ubiquitin protein ligase 1 (MIB-1) index and the presence of epithelioid cells (13) . Risk classification was based on tumor size and the MIB-1 index (14) . C-KIT expression in all GIST samples was confirmed by immunohistochemical staining (CD117 antibody, DAKO Japan Corp., Tokyo, Japan). The clinicopathological features of the 112 GIST patients are listed in Supplementary data, Table S1 , and are summarized in Table 1 . The ethical committees of the National Cancer Center and the Juntendo University approved this study. Written informed consent for inclusion in this study was obtained from all the patients examined.
WESTERN BLOTTING
Protein samples previously obtained from the primary tumor tissues were subjected to western blotting as outlined in our previous report (10) . In brief, 3 and 10 mg protein samples were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS -PAGE) (ATTO, Tokyo, Japan) and 2D-PAGE (IPG gel, 24 cm, pI 3 -10, GE Healthcare, Uppsala, Sweden), respectively. The separated proteins were electrophoretically transferred to a nitrocellulose membrane. After blocking with skimmed milk for 1 h, the membrane was incubated with primary antibody at 48C overnight. The dilutions of primary antibodies were as follows: our original antibody (10), 1:1000, and the commercial antibody (sc-80531, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), 1:500. The membrane was incubated with horseradish peroxidaseconjugated secondary antibody (1:1000 dilution, GE Healthcare) for 1 h at room temperature. Pfetin expression was detected by enhanced chemiluminescence (ECL Plus; GE Healthcare), and images were captured by an LAS-3000 image analyzer (Fujifilm, Tokyo, Japan).
IMMUNOHISTOCHEMISTRY
Pfetin expression was examined immunohistochemically using paraffin-embedded tissues as described in our previous report (10) . In brief, 4 mm-thick tissue sections were autoclaved in 10 mmol/l citrate buffer ( pH 6.0) at 1218C for 30 min and incubated with the commercial monoclonal antibody against pfetin (1:150 dilution) or our original monoclonal antibody against pfetin (1:1000 dilution) (10) . Immunostaining was carried out by the streptavidin -biotin peroxidase method using a Strept ABC Complex/horseradish peroxidase KIT (DAKO). A pathologist (A.Y.) and a clinician (D.K.) reviewed the sections stained with anti-pfetin antibody. Both were blinded to the clinical data (age, sex, anatomical site and outcome). In accordance with our previous report, cases in which .20% of tumor cells were stained with the anti-pfetin antibody were considered pfetin-positive, whereas those in which ,20% of tumor cells were stained with the anti-pfetin antibody were considered pfetin-negative (10).
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STATISTICAL ANALYSIS
All statistical analyses were carried out using the x 2 test or Fisher's exact test in cross tables to assess the relationships between pfetin expression and clinico-pathological factors. The tumor-specific and disease-free survivals were calculated from the time of initial resection of the primary tumor until death from tumor-specific causes or until the first evidence of metastasis and recurrence, respectively. All time-to-event endpoints were computed by the Kaplan -Meier method (15) . Patients who died of causes unrelated to GIST were subsequently excluded from the study. Potential prognostic factors were identified by univariate analysis using the log-rank test. Independent prognostic factors were evaluated using Cox's proportional hazards regression model (16) with significant 
RESULTS
WESTERN BLOTTING AND SDS -PAGE CHARACTERIZATION OF THE COMMERCIAL ANTIBODY AGAINST PFETIN
Our original monoclonal antibody recognized pfetin isoforms and detected two protein bands in western blotting and SDS -PAGE (10). The commercial antibody exhibited double protein bands at 37 kDa, the same molecular weight as the protein bands obtained by our original monoclonal antibody (Fig. 1A) . Moreover, both antibodies detected a higher expression level of pfetin in patients with a favorable prognosis than in those who did not (Fig. 1A) . The commercial antibody generated a non-specific protein band, and the intensities of this non-specific protein band were similar among patients with different prognosis (Fig. 1A) .
WESTERN BLOTTING AND 2D-PAGE CHARACTERIZATION OF THE COMMERCIAL ANTIBODY AGAINST PFETIN
Our previous report demonstrated that pfetin exists as isoforms, probably due to phosphorylation and our original monoclonal antibody recognized these by western blotting and 2D-PAGE (10). Both our original antibody and the commercial antibody detected pfetin isoforms by western blotting and 2D-PAGE (Fig. 1B and C) . However, the commercial antibody reacted with two additional protein spots, g and h (Fig. 1C) . According to its molecular weight, protein spot g may correspond to the non-specific protein band described in Western Blotting and SDS -PAGE Characterization of the Commercial Antibody Against Pfetin section, which displayed equal intensity regardless of the differing prognostic backgrounds (Fig. 1A, right) . The relative intensities of the protein spots corresponding to pfetin differed between our original antibody and the commercial antibody (Fig. 1B and C) . These observations suggest that while these two antibodies have similar reactivity toward pfetin overall, there are also slight differences between them.
LOCALIZATION AND EXPRESSION OF PFETIN IN PRIMARY GIST
Immunohistochemistry with the commercial antibody revealed diffuse staining of pfetin in the membranes and cytoplasm of the tumor cells (Fig. 2) . High pfetin expression was observed in sample J-60, obtained from a patient with a good outcome ( Fig. 2A , Supplementary data, Table S1 ), while low pfetin expression was observed in sample J-14, from a patient with a poor outcome (Fig. 2B , Supplementary data, Table S1 ). The correlation between pfetin expression level and favorable prognosis in the GIST patients was consistent with that in our previous study (10) .
SURVIVAL ANALYSES OF PFETIN EXPRESSION IN GIST CASES
We immunohistochemically examined pfetin expression using the commercial antibody to correlate expression levels with Figure 1 . Characterization of commercial antibody by western blotting. Western blotting and SDS-PAGE using our original antibody (A, left) and the commercial antibody (A, right). Samples N1 and N2 were from patients with no metastases during more than 2 years of observation, and samples N3 and N4 were from patients with metastases within 1 year of surgery. Arrows indicate detected protein bands with the expected molecular weight. Arrowhead indicates the protein bands with the unexpected molecular weight. Note that both antibodies detected the same two protein bands. Western blotting and 2D-PAGE was performed using our original antibody (B) and the commercial antibody (C). (a -f) indicate the protein spots commonly observed between the two antibodies while (g) and (h) correspond to the protein spots unique to the commercial antibody.
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Validation study of pfetin in GIST using a commercial antibody metastasis after surgery in the GIST patients. Kaplan -Meier survival analysis revealed that pfetin expression inversely and significantly correlated with metastasis in the 40 cases from the Juntendo Shizuoka Hospital (Fig. 3A) . Disease-free survival periods were longer in pfetin-positive cases than in pfetinnegative cases; the disease-free survival rate was 90.32 and 44.44% for pfetin-positive and pfetin-negative cases, respectively (P ¼ 0.0052; log-rank test). Immunohistochemically, we also found a significant correlation between the pfetin expression measured by the commercial antibody and metastasis-free survival in the Juntendo University Hospital cases (Fig. 3B) . The disease-free survival rate was 87.72 and 46.67% for pfetinpositive and pfetin-negative cases, respectively (P ¼ 0.0017; log-rank test), in the 72 cases from Juntendo University Hospital (Fig. 3B) . When all the 112 cases were combined, the disease-free survival rate was 88.64 and 45.83% for Table S1 . Jpn J Clin Oncol 2013;43(6) 673
pfetin-positive and pfetin-negative cases, respectively (P , 0.0001; log-rank test) (Fig. 3C ).
PFETIN EXPRESSION AND RISK CLASSIFICATION
We performed univariate and multivariate analyses and found that pfetin expression was an independent significant predictor of disease-free survival (P , 0.0001; relative risk ¼ 0.087; 95% confidence interval, 0.029-0.260; Table 1 ). Risk classification was also an independent prognostic factor in our analysis (Table 1) . We did not see the significant correlation between pfetin expression and primary site of tumor. Thus, we investigated the relationship between risk classification and disease-free survival. Metastasis after surgery was observed in 9 of 68 patients in the low-risk group, 5 of 22 in the intermediate-risk group and 10 of 22 in the high-risk group. In the low-risk group, nine GISTs (eight gastric and one small intestine) developed distant metastasis to liver or lung. In the intermediate-risk group, five GISTs (two gastric and three small intestine) developed distant metastasis to liver or lung.
In the high-risk group, nine GISTs (six gastric, two small intestine and one rectum) developed distant metastasis to liver or peritoneum, and one gastric GIST developed local recurrence. There was a significant correlation between the risk classification and post-operative metastasis of GIST (Fig. 4A) . We then examined the prognostic value of pfetin in each risk classification group. In the low-risk group, the disease-free survival rate was 91.23 and 72.73% for pfetin-positive and pfetin-negative patients, respectively (P ¼ 0.0198; log-rank; Fig. 4B ). In the intermediate-risk group, the disease-free survival rate was 93.75 and 33.33% for pfetin-positive and pfetin-negative patients, respectively (P ¼ 0.0429; log-rank; Fig. 4C ). In the high-risk group, the disease-free survival rate was 73.33 and 14.29% for pfetin-positive and pfetin-negative patients, respectively (P ¼ 0.1637; log-rank; Fig. 4D ).
COMPARISON BETWEEN OUR ORIGINAL ANTIBODY AND THE COMMERCIAL ANTIBODY
Concordance rate of commercial antibody and our original monoclonal antibody was 88.4% (99 of 112 cases). In 13 patients, the immunohistochemistry results from our original antibody and the commercial antibody were conflicting (Supplementary data, Table S2 ). Six cases were pfetinpositive according to the commercial antibody, but pfetinnegative according to the original monoclonal antibody; seven cases were pfetin-positive according to the original monoclonal antibody, but pfetin-negative according to the commercial 
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Validation study of pfetin in GIST using a commercial antibody antibody. Based on their pfetin expression, these 13 patients did not have significant survival differences. According to the pfetin expression measured by the commercial antibody, the site of tumor origin was significantly different.
DISCUSSIONS
Development of a biomarker to predict metastasis after surgery is critical for GIST patients in order to improve therapeutic strategies using the tyrosine kinase inhibitor imatinib mesylate (2 -5). However, no prognostic molecular biomarkers have been established. With this in mind, we used a proteomic approach to search for a novel biomarker to predict favorable prognosis, and identified pfetin (6) . The immunohistochemical validation study of pfetin using our original monoclonal antibody has so far been successful in four hospitals (11, 12) . However, further validation will be required to fully establish its use in GIST patients. The use of a commercial antibody against pfetin would facilitate this validation step, as researchers would be able to examine pfetin expression with greater ease. We obtained discordant immunohistochemical results between our original antibody and the commercial antibody in 13 cases. Except for the site of tumor origin, we did not detect notable differences in the clinico-pathological characteristics of these 13 cases. Moreover, these 13 cases did not exhibit significant differences in clinical outcome compared with cases with concordantly pfetin-positive or pfetin-negative primary tumors (Supplementary data, Table S1 ).
In conclusion, we report the prognostic utility of a commercially available antibody for pfetin in GIST. The use of the commercial antibody for immunohistochemical validation is hoped to facilitate the introduction of pfetin as a biomarker for favorable prognosis in GIST. As there may be discrepancies in pfetin expression depending on the antibodies used, an additional biomarker may be required.
Supplementary data
Supplementary data are available at http://www.jjco. oxfordjournals.org. 
